Dosing Penalty of Erythropoiesis-Stimulating Agents After Switching From Originator to Biosimilar Preparations in Stable Hemodialysis Patients

MeSH terms

• Aged
• Aged, 80 and over
• Anemia / complications
• Anemia / drug therapy*
• Anemia / metabolism
• Anemia, Iron-Deficiency / complications
• Anemia, Iron-Deficiency / drug therapy
• Anemia, Iron-Deficiency / metabolism
• Biosimilar Pharmaceuticals / administration & dosage*
• Dose-Response Relationship, Drug
• Drug Substitution
• Epoetin Alfa / administration & dosage*
• Erythropoietin / administration & dosage*
• Female
• Hematinics / administration & dosage*
• Hemoglobins / metabolism
• Humans
• Iron / therapeutic use
• Kidney Failure, Chronic / complications
• Kidney Failure, Chronic / therapy*
• Male
• Middle Aged
• Recombinant Proteins / administration & dosage
• Renal Dialysis*
• Retrospective Studies
• Trace Elements / therapeutic use